N4 Pharma PLC
LSE:N4P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
N4P's latest stock split occurred on May 3, 2017
The company executed a 200-for-800 stock split, meaning that for every 800 shares held, investors received 200 new shares.
Before the split, N4P traded at 1.25 per share. Afterward, the share price was about 6.375.
The adjusted shares began trading on May 3, 2017. This was N4P's 2nd stock split, following the previous one in Oct 15, 2015.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
|
Apr 24, 2026
|
L
|
La Comer SAB de CV
OTC:LCMRF
|
115-for-114
x1.0087719298246
|
2.4715 2.4341 USD | 2.45 2.45 USD |
CUE
3902
MMI
N4 Pharma PLC
Glance View
N4 Pharma Plc is a pharmaceutical company, which engages in the reformulation of existing drugs and vaccines. The company is headquartered in Derby, Derbyshire and currently employs 5 full-time employees. The company went IPO on 2005-06-07. The firm is engaged in engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company is focused on developing a delivery system for vaccines and cancer treatments using its silica nanoparticle delivery system called Nuvec. Nuvec is a non-viral adjuvant delivery system that has the potential to revolutionize vaccines and cancer treatments. The company is focused on development and commercialization of medicines via its delivery system.
